Skip to main content
search

Simcyp® Offerings for Academia

Empowering Academic Excellence with the Simcyp Simulator

Email us

Simcyp Simulator for Academia

At Certara, we believe education fuels innovation. That’s why we are proud to partner with academic institutions worldwide to provide access to our industry-leading Simcyp® PBPK Simulator.

Through academic licenses, specialized workshops, research grants, and a vibrant scientific community, we empower the next generation of researchers to drive advancements in drug discovery and development.

Email [email protected] to learn more about academic licenses.

Gain access to Simcyp with a Simcyp Academic License
Apply for academic awards
Attend workshops and trainings uniquely designed for students
Build community through the Simcyp Student Chapter

Simcyp Academic Licenses

Trusted by more than 100 academic institutions, the Simcyp PBPK Simulator supports the teaching of topics such as:

Advanced pharmacokinetics for small and large molecules

Drug metabolism and disposition

Dose selection for specific populations

Dosage form design

Clinical study design and interpretation

Linking PBPK/PD – QSP modeling

Certara grants academic licenses for the Simcyp PBPK Simulator to leading academic institutions for pharmaceutical research. As part of the licensing agreement, users at new institutions must attend Simcyp workshops on model-based drug development prior to using the Simcyp PPBK Simulator in teaching and research activities.

Email [email protected] to learn more about academic licenses.

Advance Research and Teaching with Industry-Leading PBPK Modeling Software

Join a global academic community of over 100 institutions using the Simcyp PBPK Simulator to support research and education. The Simcyp PBPK Simulator, developed with a Consortium of 35+ leading pharmaceutical companies, equips your academic team with modeling software used across the drug development landscape.

  • Apply for academic awards
  • Attend hands-on workshops
  • Build expertise in model-informed drug development